October 2019 - Page 2 of 21

WednesdayOct 30, 2019 12:25 pm

HTC Extraction Systems (TSX.V: HTC) to Expand Operations with $10 Million in New Funding

HTC recently closed a bought deal private placement worth $10 million in funding Demand for hemp biomass continues to grow with the U.S. hemp-derived CBD market expected to reach $22 billion by 2022 HTC’s proprietary biomass processing methodology maximizes extraction and purification of hemp biomass After successfully raising $10 million in a private placement financing of 25 million units of the company, HTC Extraction Systems (TSX.V: HTC) is poised to expand its role in the cannabidiol (CBD) extraction market. HTC plans to use the funds for purchase of extraction, purification and refining equipment, and for general working capital purposes, the company…

WednesdayOct 30, 2019 11:51 am

Predictive Oncology Inc.’s (NASDAQ: POAI) Valuable Database Offers Hope to Cancer Patients of Today and Tomorrow

Predictive Oncology Inc. harnessing the power of artificial intelligence and its rich database of tumor data to help clinicians match cancer patients with most effective drug treatments Like Amazon’s customer dataset, POAI’s deep database of historical tumor information positions it for industry success Precision medicine is a data problem – demonstrates the huge value of data and those companies that generate it When shopping on Amazon, it seems like the multinational technology company knows its customers intimately. Every product filtered into a search query response seems carefully curated to match each customer. This ability to leverage big data has pushed…

WednesdayOct 30, 2019 11:18 am

VPR Brands LP (VPRB) Among Industry Players Awaiting Final USDA Hemp Rules

VPRB among key players anticipating United States Department of Agriculture (USDA) final draft rules on industrial hemp USDA’s Deputy Secretary Stephen Censky noted the regulations’ release to be expected within weeks, ahead of 2020 planting season Interim rules drafted include input from myriad voices; intend to relieve burden on producers, stakeholders VPR Brands LP (OTCQB: VPRB), a multi-vertical tiered technology holding company in the cannabis space including vaping, joins other hemp industry players in their anticipation of the United States Department of Agriculture’s (USDA) release of an interim final rule for its Hemp Program. This announcement is timed in advance…

TuesdayOct 29, 2019 4:30 pm

Citius Pharmaceuticals Inc. (NASDAQ: CTXR) Starts Presentation at Dawson James Small Cap Growth Conference

Citius Pharmaceuticals Inc. (NASDAQ: CTXR) is a specialty pharmaceutical company focused on anti-infectives, cancer care and unique prescription products that use innovative, patented or proprietary formulations of previously approved pharmaceutical ingredients. By using previously approved drugs with substantial safety and efficacy data, the company seeks to reduce risks associated with pharmaceutical product development and regulatory requirements. The company develops products that have intellectual property protection and competitive advantages to existing therapeutic approaches. Citius intends to achieve leading market positions by providing therapeutic products that address unmet medical needs. For more information, visit the company's website at www.citiuspharma.com. About NetworkNewsWire NetworkNewsWire (NNW)…

TuesdayOct 29, 2019 4:30 pm

BioCardia (NASDAQ: BCDA) Starts Presentation at Dawson James Small Cap Growth Conference

BioCardia (NASDAQ: BCDA) is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP™ and CardiALLO™ cell therapies are the company's biotherapeutic product candidates in clinical development. BioCardia's current products include the Helix™ Biotherapeutic Delivery System and the Morph® steerable guide and sheath catheter portfolio, including the new AVANCE™ Steerable Introducer family. BioCardia also partners with other biotherapeutic companies to provide its Helix systems and clinical support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. For more information, visit the company's website at www.biocardia.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news…

TuesdayOct 29, 2019 4:05 pm

DelMar Pharmaceuticals Inc. (NASDAQ: DMPI) Starts Presentation at Dawson James Small Cap Growth Conference

DelMar Pharmaceuticals (NASDAQ: DMPI) concentrates on the development and commercialization of new therapies for cancer patients who have limited or no treatment options. Focused on understanding tumor biology and mechanisms of treatment resistance, DelMar identifies biomarkers to personalize new therapies in indications where patients are failing, or are unable to tolerate, standard-of-care treatments. The company's current pipeline is based around VAL-083, a "first-in-class", small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers including central nervous system, ovarian and other solid tumors in U.S. clinical trials sponsored by the NCI. Delmar is…

TuesdayOct 29, 2019 4:05 pm

Lineage Cell Therapeutics Inc. (NYSE: LCTX) Starts Presentation at Dawson James Small Cap Growth Conference

Lineage Cell Therapeutics (NYSE: LCTX) is a clinical-stage biotech company developing novel cell therapies for unmet medical needs. The company's programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. Utilizing its unique platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage is developing three cell…

TuesdayOct 29, 2019 3:40 pm

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) Starts Presentation at Dawson James Small Cap Growth Conference

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) is a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases such as ALS, Multiple Sclerosis and Parkinson's Disease. BrainStorm holds the exclusive worldwide rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. FDA and the European Medicines Agency in ALS. BrainStorm is currently enrolling a phase 3 pivotal trial in ALS, investigating repeat-administration of autologous MSC-NTF cells. The pivotal study is intended to support a filing for U.S. FDA approval…

TuesdayOct 29, 2019 3:40 pm

BeyondSpring Inc. (NASDAQ: BYSI) Starts Presentation at Dawson James Small Cap Growth Conference

BeyondSpring (NASDAQ: BYSI) is a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies. BeyondSpring employs a novel, scalable business model that integrates U.S. and Chinese clinical resources, aimed at creating maximum value for all stakeholders. BeyondSpring also intends to pursue internal development and selective acquisitions of pharmaceutical products with a clear, near-term pathway to global approvals. BeyondSpring has a robust drug development pipeline at various clinical and pre-clinical stages. The company's lead asset, Plinabulin, is in a phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC)…

TuesdayOct 29, 2019 3:15 pm

Dare Bioscience Inc. (NASDAQ: DARE) Starts Presentation at Dawson James Small Cap Growth Conference

Dare Bioscience (NASDAQ: DARE) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's sexual health, vaginal health, fertility and contraception. The company is identifying, developing and bringing to market a portfolio of novel, differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women's health. Dare's product portfolio includes potential first-in-class candidates in clinical development: Ovaprene, a non-hormonal, monthly contraceptive vaginal ring; and Sildenafil Cream, a potential treatment for female sexual arousal disorder, as well as a proprietary solution-to-gel formulation of clindamycin to treat bacterial vaginosis via a single application. For more information,…

Financial news and publishing for public and private companies

Contact us: 212.418.1217

Month: October 2019